Table 4 Comparison of susceptibility profiles between ESBL and non-ESBL producing isolates
Antibiotic | ESBL (138) | Non-ESBL (235) | P- value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S | I | R | S | I | R | ||||||||
% | N | % | N | % | N | % | N | % | N | % | N | ||
Amoxicillin | 8.7 | 12 | 11.6 | 16 | 79.7 | 110 | 19.1 | 45 | 11.9 | 28 | 68.9 | 162 | 0.022 |
Amoxicillin-clavulanic acid | 8 | 11 | 29.7 | 24 | 71.9 | 86 | 17.9 | 42 | 10.2 | 41 | 62.3 | 169 | < 0.001 |
Cefuroxime | 18.1 | 25 | 26.8 | 37 | 55.1 | 76 | 40.9 | 96 | 23.4 | 55 | 35.7 | 84 | < 0.001 |
Cephalexin | 31.2 | 43 | 10.1 | 14 | 58.7 | 81 | 43.8 | 103 | 12.3 | 29 | 43.8 | 103 | 0.02 |
Cefotaxime | 22.5 | 31 | 0 | 0 | 77.5 | 107 | 60.4 | 142 | 5.1 | 12 | 34.5 | 81 | < 0.001 |
Ceftriaxone | 24.6 | 34 | 0 | 0 | 75.4 | 104 | 57.4 | 135 | 6.4 | 15 | 36.2 | 85 | < 0.001 |
Ceftazidime | 15.2 | 21 | 0 | 0 | 84.8 | 117 | 47.2 | 111 | 12.8 | 30 | 40 | 94 | < 0.001 |
Imipenem | 32.6 | 45 | 40.6 | 56 | 26.8 | 37 | 40.9 | 96 | 36.1 | 85 | 23 | 54 | 0.272 |
Amikacin | 73.6 | 173 | 1.3 | 3 | 25.1 | 59 | 75.4 | 104 | 0.7 | 1 | 23.9 | 33 | 0.576 |
Gentamicin | 38.4 | 53 | 23.2 | 32 | 37.7 | 52 | 48.5 | 114 | 19.1 | 45 | 32.3 | 76 | 0.165 |
Co-trimoxazole | 17.4 | 24 | 23.2 | 32 | 59.4 | 82 | 79 | 33.6 | 27 | 11.5 | 54.9 | 129 | < 0.001 |
Ciprofloxacin | 39.9 | 55 | 34.8 | 48 | 25.4 | 35 | 46.8 | 110 | 23 | 54 | 30.2 | 71 | 0.046 |
Doxycycline | 14.5 | 20 | 30.4 | 42 | 55.1 | 76 | 31.1 | 73 | 9.4 | 22 | 59.6 | 140 | < 0.001 |